GUJARAT THEMIS BIOSYN
|
GUJARAT THEMIS BIOSYN Last 5 Year Financial Ratios History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.48 | 8.14 | 39.90 | 30.03 | 20.77 |
| CEPS(Rs) | 4.97 | 5.75 | 5.56 | 4.21 | 2.93 |
| DPS(Rs) | 0.67 | 1.00 | 5.40 | 11.00 | - |
| Book NAV/Share(Rs) | 22.79 | 27.72 | 102.66 | 71.12 | 48.14 |
| Tax Rate(%) | 25.58 | 25.43 | 25.17 | 26.10 | 26.18 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 45.65 | 46.36 | 49.62 | 50.54 | 44.53 |
| EBIT Margin(%) | 43.70 | 46.85 | 52.32 | 52.12 | 46.23 |
| Pre Tax Margin(%) | 43.46 | 46.72 | 52.21 | 51.40 | 45.14 |
| PAT Margin (%) | 32.34 | 34.84 | 39.07 | 37.98 | 33.32 |
| Cash Profit Margin (%) | 35.91 | 36.92 | 40.80 | 39.93 | 35.24 |
| Performance Ratios | |||||
| ROA(%) | 17.44 | 27.65 | 35.81 | 37.08 | 35.65 |
| ROE(%) | 21.69 | 33.76 | 45.92 | 50.35 | 53.82 |
| ROCE(%) | 27.48 | 45.40 | 61.51 | 67.91 | 67.89 |
| Asset Turnover(x) | 0.54 | 0.79 | 0.92 | 0.98 | 1.07 |
| Sales/Fixed Asset(x) | 2.73 | 3.57 | 4.11 | 4.27 | 3.82 |
| Working Capital/Sales(x) | 4.80 | 5.41 | 3.19 | 1.88 | 1.91 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.37 | 0.28 | 0.24 | 0.23 | 0.26 |
| Receivable days | 70.51 | 48.29 | 52.91 | 63.29 | 70.42 |
| Inventory Days | 10.13 | 19.29 | 32.26 | 28.06 | 24.34 |
| Payable days | 193.03 | 99.37 | 114.42 | 115.10 | 132.50 |
| Valuation Parameters | |||||
| PER(x) | 62.89 | 32.42 | 3.44 | 13.57 | 9.80 |
| PCE(x) | 56.65 | 45.89 | 16.47 | 12.91 | 9.27 |
| Price/Book(x) | 12.35 | 14.29 | 6.69 | 5.73 | 4.23 |
| Yield(%) | 0.24 | 0.25 | 0.79 | 2.70 | - |
| EV/Net Sales(x) | 20.46 | 16.90 | 6.66 | 5.05 | 3.00 |
| EV/Core EBITDA(x) | 43.28 | 34.53 | 12.32 | 9.33 | 6.22 |
| EV/EBIT(x) | 46.81 | 36.06 | 12.72 | 9.68 | 6.48 |
| EV/CE(x) | 11.09 | 14.25 | 6.62 | 5.61 | 3.72 |
| M Cap / Sales | 20.34 | 16.94 | 6.72 | 5.15 | 3.27 |
| Growth Ratio | |||||
| Net Sales Growth(%) | -11.20 | 14.45 | 29.19 | 26.82 | 6.39 |
| Core EBITDA Growth(%) | -14.23 | 3.59 | 29.18 | 42.43 | 29.97 |
| EBIT Growth(%) | -17.17 | 2.48 | 29.70 | 42.99 | 30.09 |
| PAT Growth(%) | -17.56 | 2.06 | 32.88 | 44.55 | 27.48 |
| EPS Growth(%) | -45.04 | -79.59 | 32.88 | 44.55 | 27.47 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.12 | - | - | - | 0.04 |
| Current Ratio(x) | 1.84 | 1.87 | 2.30 | 2.93 | 2.84 |
| Quick Ratio(x) | 1.71 | 1.78 | 1.89 | 2.57 | 2.60 |
| Interest Cover(x) | 181.05 | 347.14 | 440.64 | 72.31 | 42.66 |
| Total Debt/Mcap(x) | 0.01 | - | - | - | 0.01 |
Compare Financial Ratios of peers of GUJARAT THEMIS BIOSYN
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GUJARAT THEMIS BIOSYN | ₹4,450.5 Cr | 4.3% | -1.1% | 30.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹424,982.0 Cr | -0.7% | -0.5% | -3.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹172,878.0 Cr | 2.8% | 2.2% | 10.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹129,095.0 Cr | 1.5% | 3.4% | 12.4% | Stock Analytics | |
| CIPLA | ₹122,175.0 Cr | 0.8% | 0.1% | 3.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,154.0 Cr | 0.4% | 3.2% | 0.3% | Stock Analytics | |
GUJARAT THEMIS BIOSYN Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GUJARAT THEMIS BIOSYN | 4.3% |
-1.1% |
30.6% |
| SENSEX | 0.4% |
-0.1% |
6.1% |
You may also like the below Video Courses
